drugset / Trial / NCT01843127

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

NCT01843127

Phase 1 Completed 24 enrolled Gilead Sciences
RandomizedCrossoverSingle-blindTreatment

Summary

To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).

Timeline

Start
2013-04
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Exenatide Peptide
Comparator Ranolazine Small molecule